Abstract
Neuroblastoma (NB) is the most common extracranial malignant solid tumors of childhood, and the majority of these high-risk tumors is resistant to nearly all the treatments and has a significantly worse outcome. The mammalian target of rapamycin (mTOR) plays a critical role in oncogenesis and cancer progression of many tumors. This review will describe the function of mTOR, its genetic regulation in pediatric neuroblastoma, and its value as a target for inhibition by anticancer agents for patients with NB.
MeSH terms
-
Adolescent
-
Antineoplastic Agents / therapeutic use
-
Child
-
Child, Preschool
-
Drug Delivery Systems / methods
-
Female
-
Humans
-
Infant
-
Male
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism*
-
Neuroblastoma / drug therapy
-
Neuroblastoma / genetics
-
Neuroblastoma / metabolism*
-
Neuroblastoma / pathology
-
Signal Transduction*
-
TOR Serine-Threonine Kinases / genetics
-
TOR Serine-Threonine Kinases / metabolism*
Substances
-
Antineoplastic Agents
-
Neoplasm Proteins
-
MTOR protein, human
-
TOR Serine-Threonine Kinases